Aurora Cannabis introduced its new high‑THC sativa cultivar, Black Jelly, to the Polish market on December 11, 2025. The cultivar, derived from Alien Cake 3030 × T037, contains 27% THC and less than 1% CBD, positioning it as a premium option for patients requiring potent medical cannabis.
The launch expands Aurora’s high‑potency medical flower portfolio in Poland, one of Europe’s fastest‑growing medical cannabis markets. Poland’s market is projected to reach €72 million in 2025 and grow to USD 27.4 million by 2030, a CAGR of 26.4% from 2024. Aurora’s entry with Black Jelly taps into this expanding demand for high‑potency products.
Aurora’s manufacturing of Black Jelly in its Canadian GACP and EU‑GMP certified facilities underscores the company’s commitment to quality and regulatory compliance. The dense, large flowers feature green and orange hues and a terpene profile described as sweet black liquorice with fruity undertones, reflecting Aurora’s advanced genetics program.
Management highlighted the strategic importance of the Polish launch. Senior VP of Aurora Europe, Andreas Dotterweich, said the company is uniquely positioned to bring proprietary cultivars to the market thanks to its breeding program and cultivation excellence. He added that prescribers demand reliable, high‑potency options, and Aurora is proud to meet that need.
Aurora’s broader financial performance supports the launch. In Q3 2025, the company reported record net revenue of C$88.2 million, up 37% YoY, with medical cannabis revenue at C$68.1 million, up 51% YoY. International revenue grew 112% in Q3 2025, representing 60% of global medical cannabis net revenue, indicating strong momentum that the Black Jelly launch will further accelerate.
The addition of Black Jelly to Aurora’s Polish portfolio strengthens its competitive position and supports continued revenue growth in the international medical segment. The launch aligns with Aurora’s “medical cannabis first” strategy and positions the company to capture a larger share of Poland’s high‑potency market as demand continues to accelerate.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.